Presbyopia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Presbyopia Marketed and Pipeline Drugs Report Overview
Presbyopia is the irreversible loss of the accommodative ability of the eye that occurs due to aging. Accommodation refers to the ability of the eye to increase the refractive power of its crystalline lens to focus near objects on the retina. The most significant decrease in accommodative power occurs in between the ages of 20 and 50. In the first two decades of life, the accommodative amplitude is relatively stable, in the range of 7–10 diopters. By the age of 50, accommodative amplitude typically decreases to about 0.50 diopters. This decline occurs as a natural result of aging and will ultimately affect any person reaching an advanced enough age. If uncorrected or under-corrected, presbyopia can significantly impact a patient’s quality of life.
| Key Mechanisms of Action (Pipeline) | · Receptor Agonist
· Receptor Antagonist |
| Top Sponsors (Marketed and Pipeline Drugs) | · Allergan Ltd
· Orasis Pharmaceuticals · Lenz Therapeutics Operations, Inc · Novartis AG · Ocuphire Pharma Inc |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
The presbyopia marketed and pipeline drugs market research report includes an assessment of the disease epidemiology. It provides leading marketed products with sales forecast, pricing, and reimbursement, and late-to-mid-stage pipeline products with phase transition success rate (PTSR) and likelihood of approval (LoA) for presbyopia. The report also analyzes the clinical and commercial landscapes of Presbyopia, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
Presbyopia Pipeline Drugs Market Segmentation by Mechanisms of Action
The key MoA of the marketed drugs for Presbyopia includes receptor agonist and receptor antagonist. Most of the pipeline drugs follow receptor agonist MoA in 2024 in the presbyopia market.
Presbyopia Pipeline Drugs Market Analysis by Mechanisms of Action, 2024 (%)
Buy the Full Report to Know More about the MoA of Presbyopia Pipeline Drugs
Presbyopia Marketed and Pipeline Drugs Market – Competitive Landscape
A few of the top sponsors in the presbyopia marketed and pipeline drugs market are Allergan Ltd, Orasis Pharmaceuticals, Lenz Therapeutics Operations, Inc, Novartis AG, and Ocuphire Pharma Inc among others. Allergan sponsored the highest number of trials, followed by Orasis Pharmaceuticals.
Presbyopia Marketed and Pipeline Drugs Market – Sponsors Analysis with Breakdown by Phase, 2024 (%)
Buy the Full Report for More Sponsor Insights into the Presbyopia Marketed and Pipeline Drugs Market
Download a Free Report Sample
Segments Covered in the Report
Presbyopia Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2024)
- Receptor Agonist
- Receptor Antagonist
Scope
GlobalData’s Presbyopia: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Presbyopia market.
- Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Presbyopia market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which is the leading MoA for Presbyopia pipeline drugs in 2024?
Most of the drugs follow receptor agonist MoA in 2024 in the Presbyopia drugs market.
-
Which are the top sponsors in the Presbyopia marketed and pipeline drugs market?
A few of the top sponsors in the Presbyopia marketed and pipeline drugs market are Allergan Ltd, Orasis Pharmaceuticals, Lenz Therapeutics Operations, Inc, Novartis AG, and Ocuphire Pharma Inc among others.
-
Which company sponsored the highest number of trials in the Presbyopia marketed and pipeline drugs market?
Allergan sponsored the highest number of trials in the Presbyopia marketed and pipeline drugs market.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Presbyopia reports

